{"protocolSection":{"identificationModule":{"nctId":"NCT02960880","orgStudyIdInfo":{"id":"18735"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists","officialTitle":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists"},"statusModule":{"statusVerifiedDate":"2017-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-10-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-12-31","type":"ACTUAL"},"completionDateStruct":{"date":"2016-12-31","type":"ACTUAL"},"studyFirstSubmitDate":"2016-10-12","studyFirstSubmitQcDate":"2016-11-08","studyFirstPostDateStruct":{"date":"2016-11-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-12-22","lastUpdatePostDateStruct":{"date":"2017-12-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Rivaroxaban, Phenprocoumon, retrospective cohort study, Non-Valvular Atrial fibrillation, NVAF"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":99999,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","description":"NVAF patients who were newly initiated on Rivaroxaban for stroke prevention","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY597939)"]},{"label":"Phenprocoumon","description":"NVAF patients who were newly initiated on Phenprocoumon for stroke prevention","interventionNames":["Drug: Phenprocoumon (branded and generics)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY597939)","description":"15mg, 20mg","armGroupLabels":["Rivaroxaban"]},{"type":"DRUG","name":"Phenprocoumon (branded and generics)","description":"Individually adjusted dose","armGroupLabels":["Phenprocoumon"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Risk of ischemic stroke estimated as the number of hospitalizations with the ICD-10-GM diagnosis","timeFrame":"Within time of drug exposure (Retrospective period of 5 years and 3 months)"},{"measure":"Risk of intracranial hemorrhage (ICH) estimated as the number of hospitalizations with the ICD-10-GM diagnosis","timeFrame":"Within time of drug exposure (Retrospective period of 5 years and 3 months)"}],"secondaryOutcomes":[{"measure":"Risk of ischemic stroke or ICH estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis","timeFrame":"Within time of drug exposure (Retrospective period of 5 years and 3 months)"},{"measure":"Risk of systemic embolism (SE) estimated as the number of hospitalizations with the ICD-10-GM diagnosis","timeFrame":"Within time of drug exposure (Retrospective period of 5 years and 3 months)"},{"measure":"Risk of transient ischemic attack (TIA) estimated as the number of hospitalizations with the ICD-10-GM diagnosis","timeFrame":"Within time of drug exposure (Retrospective period of 5 years and 3 months)"},{"measure":"Risk of ischemic stroke or SE or TIA estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis","timeFrame":"Within time of drug exposure (Retrospective period of 5 years and 3 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* First dispense date of Rivaroxaban (15mg or 20mg - PZN based) or Phenprocoumon (PZN based) between January 1, 2012 and December 31, 2015\n* At least two verified outpatient diagnoses or one inpatient diagnosis (main or secondary diagnosis) of NVAF (ICD-10 GM I48.0/I48.1/I48.2/I48.9) in the individual time frame of 4 quarters before the index date (pre-index period) or within the index quarter\n* Patients will be required to have 4 quarters of enrollment for the assessment of baseline characteristics and be observable and insured in the database for at least one day after their individual index date (post-index period)\n* â‰¥ 18 years of age\n\nExclusion Criteria:\n\n* Patients with valvular AF \\[4 quarters prior to the index date\\]\n* Pregnancy \\[4 quarters prior to index date\\]\n* Malignant cancers \\[4 quarters prior to the index date or \"condition after\"\\]\n* Transient cause of AF \\[4 quarters prior to index date\\]\n* Patients with VTE (pulmonary embolism or DVT) \\[60 days before index\\]\n* Patients with major surgery defined as hip or knee replacement \\[60 days before index\\]\n* Prescriptions of OACs (Rivaroxaban, VKA, Dabigatran, Apixaban) before index date \\[4 quarters prior to index date\\]\n* Patients receiving more than one anticoagulant substance (Apixaban, Dabigatran, Rivaroxaban or Phenprocoumon) or more than one dosage of a substance on the index date\n* For sensitivity analysis : Patient with any of the events defined in the combined endpoints \\[4 quarters prior to index date or \"condition after\"\n* Patients with dialysis \\[4 quarters prior to index date\\]","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients newly initiated with Rivaroxaban or Phenprocoumon with an NVAF diagnosis from January 1, 2012 through December 31, 2015. Patients will be identified from the HRI research database, a complete longitudinal dataset of patients under statutory health insurance in Germany.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Multiple Locations","country":"Germany"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"},{"id":"D000010644","term":"Phenprocoumon"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","relevance":"LOW"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M13239","name":"Phenprocoumon","asFound":"Viagra","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","relevance":"LOW"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}